EODData

MEMBERSHIP REGISTER LOG IN

OTCBB, AKESF: Akeso Inc

14 Nov 2025
LAST:

15.25

CHANGE:
 0.30		OPEN:
15.45		HIGH:
15.45		ASK:
0.00		VOLUME:
800
CHG(%):
2.01		PREV:
14.95		LOW:
15.25		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
14 Nov 2515.4515.4515.2515.25800
12 Nov 2514.9515.0013.9514.95900
10 Nov 2514.4015.0014.4014.68800
07 Nov 2514.4014.4814.4014.40200
05 Nov 2513.7313.7313.7313.73400
04 Nov 2513.2314.3013.2314.30800
03 Nov 2515.3915.4615.3915.461.8K
31 Oct 2514.2014.6414.2014.641.5K
30 Oct 2515.2315.2314.0714.16600
29 Oct 2514.5514.6214.5514.55500

COMPANY PROFILE

Name:Akeso Inc
About:Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, liver cancer, and esophageal cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer. It is also developing AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, and recurrent or refractory classical Hodgkin lymphoma; AK109, a PD-1 monoclonal antibody to treat G/GEJ patients; penpulimab, a PD-1 for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC); and tagitanlimab, a PD-L1 for treating recurrent or metastatic NPC. In addition, the company develops AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia and mixed hyperlipidemia; AK101, an IL-12/IL-23 monoclonal antibody to treat moderate-to-severe psoriasis and ulcerative colitis; AK111, an IL-17 monoclonal antibody to treat moderate-to-severe psoriasis and ankylosing spondylitis; and AK120, an IL-4R monoclonal antibody to treat moderate-to-severe atopic dermatitis. Further, its preclinical product includes AK120 to treat moderate-to-severe atopic dermatitis. The company was founded in 2012 and is headquartered in Zhongshan, the People's Republic of China.
Sector:Healthcare
Industry:Biotechnology
Address:No. 6, Shennong Road, Zhongshan, China, 528437
Website:https://www.akesobio.com
FIGI:BBG012DWYQZ6

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:14.604.4%
MA10:14.614.4%
MA20:15.051.3%
MA50:17.0211.6%
MA100:16.8310.4%
MA200:13.2315.2%
STO9:87.66 
STO14:85.88 
RSI14:50.97
WPR14:-14.12 
MTM14:0.22
ROC14:0.01 
ATR:0.84 
Week High:15.451.3%
Week Low:13.959.3%
Month High:16.206.2%
Month Low:13.2315.2%
Year High:23.1551.8%
Year Low:6.81123.9%
Volatility:21.03